Givinostat - Italfarmaco
Alternative Names: DUVYZAT; Givinostat hydrochloride hydrate- Italfarmaco; Givinostat hydrochloride monohydrate - Italfarmaco; ITF-2357Latest Information Update: 28 May 2024
At a glance
- Originator Italfarmaco; Sanford Burnham Prebys Medical Discovery Institute
- Developer Italfarmaco
- Class Amines; Anti-inflammatories; Antineoplastics; Antirheumatics; Benzene derivatives; Carbamates; Ethylamines; Hydroxamic acids; Naphthalenes; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Duchenne muscular dystrophy
- Phase III Polycythaemia vera
- Phase II Myeloproliferative disorders
- Discontinued Chronic lymphocytic leukaemia; Crohn's disease; Diffuse large B cell lymphoma; Hereditary autoinflammatory diseases; Hodgkin's disease; Juvenile rheumatoid arthritis; Multiple myeloma
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Polycythaemia-vera(In volunteers) in Canada (PO, Suspension)
- 26 Mar 2024 Chemical structure information updated
- 22 Mar 2024 ITF Therapeutics (a subsidiary of Italfarmaco) intends to launch givinostat for Duchenne muscular dystrophy in the US (PO) in the third quarter of 2024 (ITF Therapeutics website, March 2024)